Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice

Wang, H; Zhang, HW; Srinivasan, V; Tao, JG; Sun, W; Lin, X; Wu, T; Boyce, BF; Ebetino, FH; Boeckman, RK; Xing, LP

Xing, LP (reprint author), Dept Pathol & Lab Med, 601 Elmwood Ave, Rochester, NY 14642 USA.

JOURNAL OF BONE AND MINERAL RESEARCH, 0; ():

Abstract

Bortezomib (Btz) is a proteasome inhibitor approved by the FDA to treat multiple myeloma. It also increases bone volume by promoting osteoblast differ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索